SI3555132T1 - Protitelesa proti LIF in njihove uporabe - Google Patents

Protitelesa proti LIF in njihove uporabe

Info

Publication number: SI3555132T1
Authority: SI; Slovenia
Prior art keywords: antibodies against; against lif; lif; antibodies
Prior art date: 2016-12-19

Application number

SI201731487T

Other languages

English (en)

Inventor

Suarez Joan Seoane

Folgueira Judit Anido

Johan Fransson

Jean-Philippe Julien

Swetha Raman

Original Assignee

Medimmune Limited

Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants

Fundacio Privada Institut d'Investigacio Oncologica de Vall-Hebron, Natzaret

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-19

Filing date

2017-12-18

Publication date

2024-04-30

2017-12-18 Application filed by Medimmune Limited, Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants, Fundacio Privada Institut d'Investigacio Oncologica de Vall-Hebron, Natzaret filed Critical Medimmune Limited

2017-12-18 Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en

2024-04-30 Publication of SI3555132T1 publication Critical patent/SI3555132T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Oncology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201731487T 2016-12-19 2017-12-18 Protitelesa proti LIF in njihove uporabe SI3555132T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP16382617		2016-12-19
US201762467017P	2017-03-03	2017-03-03
EP17382683		2017-10-13
EP17840489.3A EP3555132B1 (en)	2016-12-19	2017-12-18	Antibodies against lif and uses thereof
PCT/IB2017/001677 WO2018115960A1 (en)	2016-12-19	2017-12-18	Antibodies against lif and uses thereof

Publications (1)

Publication Number	Publication Date
SI3555132T1 true SI3555132T1 (sl)	2024-04-30

Family

ID=67138942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201731487T SI3555132T1 (sl)	2016-12-19	2017-12-18	Protitelesa proti LIF in njihove uporabe

Country Status (23)

Country	Link
US (2)	US11390670B2 (sl)
EP (2)	EP3555132B1 (sl)
JP (3)	JP7100056B2 (sl)
KR (2)	KR102599557B1 (sl)
CN (2)	CN111868086B (sl)
AU (1)	AU2017381585B2 (sl)
BR (1)	BR112019012691A2 (sl)
CA (1)	CA3047528A1 (sl)
CL (2)	CL2019001717A1 (sl)
DK (1)	DK3555132T3 (sl)
ES (1)	ES2971126T3 (sl)
FI (1)	FI3555132T3 (sl)
HR (1)	HRP20240195T8 (sl)
HU (1)	HUE065241T2 (sl)
IL (2)	IL294088B2 (sl)
LT (1)	LT3555132T (sl)
MX (2)	MX2019007376A (sl)
PL (1)	PL3555132T3 (sl)
RS (1)	RS65187B1 (sl)
SA (1)	SA519402119B1 (sl)
SI (1)	SI3555132T1 (sl)
SM (1)	SMT202400065T1 (sl)
ZA (1)	ZA201904533B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20210021287A (ko) *	2018-04-12	2021-02-25	메디뮨 리미티드	암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합
WO2021110873A1 (en) *	2019-12-04	2021-06-10	Medimmune Limited	Antibodies against lif and uses thereof
TW202128748A (zh)	2020-01-24	2021-08-01	日商西斯美股份有限公司	提升抗體對抗原之親和性的方法及其用途
JP2024501739A (ja)	2020-12-31	2024-01-15	諾納生物（蘇州）有限公司	ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用
WO2022241082A1 (en) *	2021-05-14	2022-11-17	Genentech, Inc.	Agonists of trem2

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
WO1993023556A1 (en)	1992-05-08	1993-11-25	Genentech, Inc.	Antibodies to leukemia inhibitory factor
WO1993023665A1 (en)	1992-05-15	1993-11-25	Re/Map Incorporated	Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
ES2254564T3 (es)	1995-04-24	2006-06-16	Genentech, Inc.	Uso de antagonistas de factor de inhibicion de la leucemia.
MX353234B (es)	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
US6399857B1 (en) *	1999-09-22	2002-06-04	Paradigm Genetics, Inc.	Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en)	2002-04-01	2003-10-16	Human Genome Sciences, Inc.	Antibodies that specifically bind to gmad
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en)	2004-06-30	2006-01-04	Academisch Ziekenhuis Leiden	Method for detecting gluten
EP1877075A4 (en) *	2005-04-25	2008-07-30	Pfizer	ANTIBODY TO MYOSTATIN
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
WO2008043052A2 (en)	2006-10-04	2008-04-10	The Scripps Research Institute	Human antibodies neutralizing human metapneumovirus
CN101440128A (zh)	2007-11-21	2009-05-27	中国人民解放军第二军医大学	人脑胶质瘤中差异表达的蛋白及其用途
ES2363358B1 (es) *	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011041584A2 (en)	2009-09-30	2011-04-07	President And Fellows Of Harvard College	Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011057144A2 (en)	2009-11-06	2011-05-12	La Jolla Institute For Allergy And Immunology	Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh)	2010-02-25	2014-05-14	上海百迈博制药有限公司	一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en)	2010-04-05	2011-10-05	Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron	Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
SG11201506088RA (en)	2013-03-11	2015-09-29	Genzyme Corp	Hyperglycosylated binding polypeptides
US20140314741A1 (en)	2013-04-18	2014-10-23	Developmen Center For Biotechnology	Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
JP6488520B2 (ja)	2013-08-20	2019-03-27	国立研究開発法人科学技術振興機構	ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US20150056195A1 (en)	2013-08-23	2015-02-26	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
EP3049110A2 (en)	2013-09-23	2016-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for targeting tumor microenvironment and for preventing metastasis
DK3055327T3 (en)	2013-10-09	2019-03-11	Res Found Dev	Monoclonal OLFML-3 Antibodies and Uses thereof
TWI486172B (zh)	2013-11-08	2015-06-01	Univ Chang Gung	鼻咽癌治療的醫藥
KR102446386B1 (ko)	2014-01-10	2022-09-22	아납티스바이오, 아이엔씨.	인터루킨-33 (il-33)에 대한 항체
PL3129067T3 (pl)	2014-03-19	2023-05-08	Genzyme Corporation	Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
CN106687134A (zh) *	2014-09-10	2017-05-17	加利福尼亚大学董事会	通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3173483A1 (en)	2015-11-27	2017-05-31	Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron	Agents for the treatment of diseases associated with undesired cell proliferation
WO2018115960A1 (en) *	2016-12-19	2018-06-28	Mosaic Biomedicals, S.L.	Antibodies against lif and uses thereof
KR20210021287A (ko) *	2018-04-12	2021-02-25	메디뮨 리미티드	암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합
WO2019243898A2 (en) *	2018-06-18	2019-12-26	Mosaic Biomedicals Slu	Methods for improving response to anti-lif antibody treatment in individuals with cancer

2017
- 2017-12-18 SI SI201731487T patent/SI3555132T1/sl unknown
- 2017-12-18 CN CN201780086859.0A patent/CN111868086B/zh active Active
- 2017-12-18 KR KR1020197021098A patent/KR102599557B1/ko active Active
- 2017-12-18 MX MX2019007376A patent/MX2019007376A/es unknown
- 2017-12-18 JP JP2019554037A patent/JP7100056B2/ja active Active
- 2017-12-18 SM SM20240065T patent/SMT202400065T1/it unknown
- 2017-12-18 HR HRP20240195TT patent/HRP20240195T8/hr unknown
- 2017-12-18 HU HUE17840489A patent/HUE065241T2/hu unknown
- 2017-12-18 CN CN202410972902.5A patent/CN118652335A/zh active Pending
- 2017-12-18 CA CA3047528A patent/CA3047528A1/en active Pending
- 2017-12-18 EP EP17840489.3A patent/EP3555132B1/en active Active
- 2017-12-18 PL PL17840489.3T patent/PL3555132T3/pl unknown
- 2017-12-18 FI FIEP17840489.3T patent/FI3555132T3/fi active
- 2017-12-18 DK DK17840489.3T patent/DK3555132T3/da active
- 2017-12-18 IL IL294088A patent/IL294088B2/en unknown
- 2017-12-18 US US16/470,896 patent/US11390670B2/en active Active
- 2017-12-18 IL IL267450A patent/IL267450B/en unknown
- 2017-12-18 BR BR112019012691-0A patent/BR112019012691A2/pt unknown
- 2017-12-18 RS RS20240203A patent/RS65187B1/sr unknown
- 2017-12-18 AU AU2017381585A patent/AU2017381585B2/en active Active
- 2017-12-18 KR KR1020237027761A patent/KR102716931B1/ko active Active
- 2017-12-18 ES ES17840489T patent/ES2971126T3/es active Active
- 2017-12-18 EP EP23209620.6A patent/EP4321219A3/en active Pending
- 2017-12-18 LT LTEPPCT/IB2017/001677T patent/LT3555132T/lt unknown
2019
- 2019-06-17 SA SA519402119A patent/SA519402119B1/ar unknown
- 2019-06-19 CL CL2019001717A patent/CL2019001717A1/es unknown
- 2019-06-19 MX MX2024003178A patent/MX2024003178A/es unknown
- 2019-07-10 ZA ZA2019/04533A patent/ZA201904533B/en unknown
2021
- 2021-04-16 CL CL2021000950A patent/CL2021000950A1/es unknown
2022
- 2022-06-23 US US17/808,319 patent/US20230042095A1/en active Pending
- 2022-06-30 JP JP2022105552A patent/JP7459173B2/ja active Active
2024
- 2024-03-19 JP JP2024044049A patent/JP2024075682A/ja active Pending

Also Published As

Publication number	Publication date
EP4321219A2 (en)	2024-02-14
ES2971126T3 (es)	2024-06-03
IL267450A (en)	2019-08-29
KR102716931B1 (ko)	2024-10-15
RS65187B1 (sr)	2024-03-29
SMT202400065T1 (it)	2024-03-13
JP7459173B2 (ja)	2024-04-01
DK3555132T3 (da)	2024-02-05
CN111868086B (zh)	2024-07-16
EP3555132B1 (en)	2023-11-15
CL2021000950A1 (es)	2021-11-26
KR102599557B1 (ko)	2023-11-07
HRP20240195T8 (hr)	2024-05-24
CA3047528A1 (en)	2018-06-28
LT3555132T (lt)	2024-02-26
EP3555132A1 (en)	2019-10-23
BR112019012691A2 (pt)	2019-11-19
JP2022130632A (ja)	2022-09-06
KR20190122652A (ko)	2019-10-30
JP7100056B2 (ja)	2022-07-12
JP2024075682A (ja)	2024-06-04
MX2019007376A (es)	2020-02-07
CL2019001717A1 (es)	2020-02-28
KR20230125099A (ko)	2023-08-28
IL294088B1 (en)	2023-06-01
HRP20240195T1 (hr)	2024-04-26
IL294088A (en)	2022-08-01
PL3555132T3 (pl)	2024-04-22
SA519402119B1 (ar)	2023-02-19
EP4321219A3 (en)	2024-05-15
CN118652335A (zh)	2024-09-17
CN111868086A (zh)	2020-10-30
IL294088B2 (en)	2023-10-01
KR20240149987A (ko)	2024-10-15
US20230042095A1 (en)	2023-02-09
HUE065241T2 (hu)	2024-05-28
US20190352389A1 (en)	2019-11-21
IL267450B (en)	2022-07-01
FI3555132T3 (fi)	2024-02-08
AU2017381585B2 (en)	2025-02-13
JP2020512388A (ja)	2020-04-23
ZA201904533B (en)	2024-08-28
US11390670B2 (en)	2022-07-19
MX2024003178A (es)	2024-03-25
AU2017381585A1 (en)	2019-07-18

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL266738A (en)	2019-07-31	Novel antibodies and their uses
IL264970A (en)	2019-04-30	Anti-tim-3 antibodies and their use
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
IL268700A (en)	2019-10-31	Anti-PHF-tau antibodies and uses thereof
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
SG10202109691UA (en)	2021-10-28	Anti-pacap antibodies and uses thereof
ZA201800536B (en)	2019-07-31	Il-8-binding antibodies and uses thereof
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
EP3541840C0 (en)	2023-12-27	ANTI-HLA-G ANTIBODIES AND ITS USE
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
PT3292154T (pt)	2022-01-26	Anticorpos anti-her3 humano e seus usos
IL266049A (en)	2019-06-30	Antibodies against o1 and their uses
IL264417A (en)	2019-02-28	Anti-o2 antibodies and their uses
IL267450A (en)	2019-08-29	Antibodies against lif and their uses
IL266082A (en)	2019-06-30	Anti-chikv antibodies and their use
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof
PT3555132T (pt)	2024-01-24	Anticorpos contra lif e suas utilizações